cytos biotechnology ag
H1N1 Influenza Vaccine From A*STAR & Cytos Enters Phase I Trials
Singapore’s A*STAR and Switzerland’s Cytos Biotechnology AG today announced the initiation of Phase I trials for their H1N1 influenza vaccine candidate.